Home
Live Updates
Protara Therapeutics Announces Third Quarter 2023 Financial Results and Business Update : comparemela.com
Protara Therapeutics Announces Third Quarter 2023 Financial Results and Business Update
Dosing is progressing well in ADVANCED-1EXP trial evaluating TARA-002 in NMIBC patients with CIS; preliminary results expected in 1H24Company init...
Related Keywords
Germany ,
Taiwan ,
Japan ,
United States ,
German ,
Jesse Shefferman ,
Klinische Einheit ,
Justine Omalley ,
Exchange Commission ,
Protara Therapeutics Inc ,
Iv Choline Chloride Program ,
Chugai Pharmaceutical Co Ltd ,
Drug Administration ,
Company Contact ,
Protara Therapeutics Inc Nasdaq ,
Lymphatic Malformations ,
Chief Executive Officer ,
Bacillus Calmette Gu ,
Orphan Drug Designation ,
Rare Pediatric Disease Designation ,
Protara Therapeutics ,
Private Securities Litigation Reform Act ,
United States Securities ,
Preferred Stock ,
Condensed Consolidated Statements ,
Nine Months Ended ,
comparemela.com © 2020. All Rights Reserved.